EUVIMEDEUVIMED entdecken
Crossref

Gamabufotalin impedes NSCLC progression by inhibiting the mitochondrial factor CHCHD2 and modulating XAF1 expression

Yisi Cai, Xiaowei Wang, Die Xu, Yinghui Song, Lemei Zhu, Weijun Peng, Bolin Chen

Biochemical Pharmacology · 2026-05 · 247 · 117809

DOI: 10.1016/j.bcp.2026.117809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-05. Verfasst von Yisi Cai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mitochondrial Proteins, Bufanolides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Science and Technology Program of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) continues to be the primary contributor to deaths associated with cancer. Current treatments are often limited by drug resistance and toxicity, highlighting the need for novel therapeutic approaches. Building on previous findings demonstrating that Gamabufotalin (CS-6) is effective against hepatocellular carcinoma, this study explores its mechanism of action in NSCLC. The findings indicate that CS-6 suppresses the proliferation and migratory capacity of NSCLC cells in a concentration-dependent manner, while significantly inducing apoptosis. The 48-hour half-maximal inhibitory concentration (IC50) ranged from 30 to 80 nM. In xenograft models, CS-6 effectively suppressed tumor growth (P < 0.05) without causing significant systemic toxicity at effective doses (25 mg/kg and 50 mg/kg). Mechanistically, coiled-coil-helix-coiled-coil-helix domain-containing protein 2 (CHCHD2) was identified as the direct molecular target of CS-6 through Limited Proteolysis-Mass Spectrometry (LiP-MS), validated by cell thermal shift assay (CETSA), MicroScale Thermophoresis (MST), and Surface Plasmon Resonance (SPR). CHCHD2, also known as mitochondrial nuclear retrograde regulator 1 (MNRR1), is a bi-organelle regulator located primarily in the mitochondrial intermembrane space, where it controls respiratory chain stability and cristae structure, thereby regulating cell survival and apoptosis[1-3]. CHCHD2 is essential for NSCLC cell survival, as both its knockdown and overexpression reduced the efficacy of CS-6. Furthermore, transcriptomic analysis revealed that targeting CHCHD2 with CS-6 activates interferon signaling and significantly upregulates the tumor suppressor X-linked inhibitor of apoptosis (XIAP)-associated factor 1 (XAF1). In conclusion, these findings establish the mitochondrial CHCHD2-XAF1 axis as a key mediator of CS-6 activity, thereby highlighting CS-6 as a promising candidate for targeted therapy in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMitochondrial ProteinsBufanolidesNeoplasm ProteinsIntracellular Signaling Peptides and ProteinsDisease ProgressionApoptosis Regulatory ProteinsTranscription FactorsHumansAnimalsGene Expression Regulation, NeoplasticMiceMice, NudeCell Line, TumorXenograft Model Antitumor AssaysFemaleMice, Inbred BALB CDose-Response Relationship, DrugAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

ApoptosisCHCHD2GamabufotalinLimited Proteolysis-Mass SpectrometryNon-small cell lung cancerXAF1

Substanzen

Mitochondrial ProteinsBufanolidesNeoplasm ProteinsXAF1 protein, humanIntracellular Signaling Peptides and ProteinsApoptosis Regulatory ProteinsTranscription FactorsAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Department of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • Central Laboratory, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.
  • Department of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China; School of Public Health, Changsha Medical University, Changsha 410219, Chin…
  • Department of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China. Electronic address: pengweijun87@csu.edu.cn.
  • The Second Department of Thoracic Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, China. Electronic address: chenbolin@hnca.org.cn.

Förderung

  • Science and Technology Program of Hunan Province

Zitieren

APA

Cai, Y., Wang, X., Xu, D., Song, Y., Zhu, L., Peng, W., & Chen, B. (2026). Gamabufotalin impedes NSCLC progression by inhibiting the mitochondrial factor CHCHD2 and modulating XAF1 expression. Biochemical Pharmacology, 247, 117809. https://doi.org/10.1016/j.bcp.2026.117809

Vancouver

Cai Y, Wang X, Xu D, Song Y, Zhu L, Peng W, et al. Gamabufotalin impedes NSCLC progression by inhibiting the mitochondrial factor CHCHD2 and modulating XAF1 expression. Biochemical Pharmacology. 2026;247:117809. doi:10.1016/j.bcp.2026.117809

BibTeX
@article{Cai2026,
  author = {Cai, Yisi and Wang, Xiaowei and Xu, Die and Song, Yinghui and Zhu, Lemei and Peng, Weijun and Chen, Bolin},
  title = {Gamabufotalin impedes NSCLC progression by inhibiting the mitochondrial factor CHCHD2 and modulating XAF1 expression},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {247},
  pages = {117809},
  doi = {10.1016/j.bcp.2026.117809}
}
Kostenlos starten →